Literature DB >> 14565933

Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment.

Annelies Verbrugge1, Talitha de Ruiter Td, Hans Clevers, Linde Meyaard.   

Abstract

Leukocyte-associated Ig-like receptor (LAIR)-1 is an inhibitory receptor expressed on most human leukocytes. It contains two immunoreceptor tyrosine-based inhibitory motifs (ITIM) in its cytoplasmic tail and recruits phosphatases upon phosphorylation. Here we show that both ITIM are required for full inhibition of cellular responses and optimal phosphatase recruitment. Mutation of the C-terminal ITIM still allows partial inhibition of the cytotoxic activity of the NK-like YT.2C2 cells, while mutation of the N-terminal ITIM completely abolishes this inhibitory activity. In contrast, in rat basophilic leukemia (RBL) cells, both mutants of LAIR-1 are partially effective. This is reflected in phosphorylation of these mutants in the different cell types upon pervanadate treatment. However, in both YT.2C2 cells and RBL cells, only the mutant containing the N-terminal ITIM recruits Src homology 2 domain-containing tyrosine phosphatase-2 (SHP-2), while the mutant containing the C-terminal ITIM does not. In RBL cells the mutant containing only the N-terminal ITIM also binds SHP-1, although to a lesser extent than wild-type LAIR-1. We find that in Jurkat T cells Lck is required for the association of SHP-1 with LAIR-1. Co-expression with Lck in 293T cells leads to phosphorylation of both wild-type LAIR-1 and the mutant containing only the N-terminal ITIM, while the mutant lacking this ITIM is not phosphorylated. These results indicate that Lck, or another Src family kinase, is essential for the consecutive phosphorylation of the N- and C-terminal ITIM. Our data imply that the N-terminal ITIM is dominant in LAIR-1 signaling, but that both ITIM contribute to an optimal inhibitory function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14565933     DOI: 10.1093/intimm/dxg134

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

Review 1.  PD-1 signaling in primary T cells.

Authors:  James L Riley
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  Identification and characterization of the rat homologue of LAIR-1.

Authors:  Robert Jan Lebbink; Talitha de Ruiter; Guido J A Kaptijn; Linde Meyaard
Journal:  Immunogenetics       Date:  2005-05-18       Impact factor: 2.846

3.  Leukocyte-associated Ig-like receptor-1-deficient mice have an altered immune cell phenotype.

Authors:  Xiaobin Tang; Linjie Tian; Gloria Esteso; Seung-Chul Choi; Alexander D Barrow; Marco Colonna; Francisco Borrego; John E Coligan
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

Review 4.  Innate immune cells in breast cancer--from villains to heroes?

Authors:  Tim Kees; Mikala Egeblad
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-07-26       Impact factor: 2.673

5.  A single residue, arginine 65, is critical for the functional interaction of leukocyte-associated inhibitory receptor-1 with collagens.

Authors:  Xiaobin Tang; Sriram Narayanan; Giovanna Peruzzi; Akintomide Apara; Kannan Natarajan; David H Margulies; John E Coligan; Francisco Borrego
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

6.  C1q-mediated repression of human monocytes is regulated by leukocyte-associated Ig-like receptor 1 (LAIR-1).

Authors:  Myoungsun Son; Betty Diamond
Journal:  Mol Med       Date:  2015-02-05       Impact factor: 6.354

7.  Incorporation of a Ligand Peptide for Immune Inhibitory Receptor LAIR-1 on Biomaterial Surfaces Inhibits Macrophage Inflammatory Responses.

Authors:  Yoon Kyung Kim; Shu-Hui Chu; Jessica Y Hsieh; Cody M Kamoku; Andrea J Tenner; Wendy F Liu; Szu-Wen Wang
Journal:  Adv Healthc Mater       Date:  2017-10-30       Impact factor: 9.933

8.  Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1.

Authors:  Robert Jan Lebbink; Talitha de Ruiter; Jelle Adelmeijer; Arjan B Brenkman; Joop M van Helvoort; Manuel Koch; Richard W Farndale; Ton Lisman; Arnoud Sonnenberg; Peter J Lenting; Linde Meyaard
Journal:  J Exp Med       Date:  2006-06-05       Impact factor: 14.307

Review 9.  SHP-1: the next checkpoint target for cancer immunotherapy?

Authors:  H Angharad Watson; Sophie Wehenkel; James Matthews; Ann Ager
Journal:  Biochem Soc Trans       Date:  2016-04-15       Impact factor: 5.407

Review 10.  CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.

Authors:  Kyle B Lupo; Sandro Matosevic
Journal:  J Hematol Oncol       Date:  2020-06-12       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.